浙江震元(000705) - 2018 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2018 was ¥708,577,457.30, representing a 13.51% increase compared to ¥624,238,757.68 in the same period last year[7]. - Net profit attributable to shareholders was ¥14,490,905.69, up 32.05% from ¥10,973,899.66 year-on-year[7]. - The basic earnings per share increased by 32.32% to ¥0.0434 from ¥0.0328 in the previous year[7]. - Net profit attributable to the parent company rose by 32.05% from CNY 10,973,899.66 to CNY 14,490,905.69, reflecting improved overall performance[14]. - Other income skyrocketed by 1221.98% from CNY 202,500.00 to CNY 2,677,012.40, mainly due to government subsidies received[14]. Assets and Shareholder Information - The total assets at the end of the reporting period were ¥2,156,968,180.27, reflecting a 5.16% increase from ¥2,051,128,213.05 at the end of the previous year[7]. - The net assets attributable to shareholders rose by 2.07% to ¥1,397,290,590.39 from ¥1,368,925,404.70[7]. - The top shareholder, Shaoxing Zhenyuan Health Industry Group Co., Ltd., holds 19.94% of the shares, totaling 66,627,786 shares[10]. - The total number of ordinary shareholders at the end of the reporting period was 32,646[10]. Cash Flow and Expenses - The company reported a net cash flow from operating activities of -¥51,074,451.29, a slight decrease of 3.15% compared to -¥49,516,579.48 in the same period last year[7]. - Cash paid for operating activities increased by 38.75% from CNY 79,026,664.69 to CNY 109,647,068.30, driven by increased marketing expenses[15]. - Cash flow from investing activities improved by 70.11%, with net cash flow of CNY -2,892,957.10 compared to CNY -9,679,533.47 in the previous period[15]. - Financial expenses decreased significantly by 89.14%, improving from CNY -2,382,433.52 to CNY -258,657.60 due to reduced foreign exchange losses[14]. Operational Changes - Prepayments increased by 157.22% from CNY 31,929,681.96 to CNY 82,128,232.24 due to increased direct purchases from manufacturers[14]. - Other receivables rose by 105.49% from CNY 17,133,173.48 to CNY 35,206,681.59, primarily due to increased sales reserves[14]. - Sales expenses surged by 100.55% from CNY 36,096,461.15 to CNY 72,391,863.05, attributed to rapid sales growth of Zhenyuan Pharmaceutical[14]. - Management expenses increased by 54.75% from CNY 30,551,896.51 to CNY 47,278,938.21, mainly due to higher R&D investments[14]. Compliance and Governance - The company did not engage in any repurchase transactions during the reporting period[12]. - The company reported no violations regarding external guarantees or non-operating fund occupation by major shareholders during the reporting period[23][24]. - The weighted average return on equity was 1.05%, an increase of 0.21 percentage points from 0.84%[7].